Malignancy in patients with inflammatory myopathy.

Area of Science:

• Rheumatology
• Oncology
• Neurology

Background:

• Population-based cohort studies increasingly confirm associations between malignancy and inflammatory myopathies.
• Previous studies indicated a strong link, with recent data suggesting an even stronger association between polymyositis and cancer.
• New evidence verifies an association between malignant disease and inclusion body myositis for the first time.

Purpose of the Study:

• To review recent evidence on the association between malignancy and inflammatory myopathies, including dermatomyositis, polymyositis, and inclusion body myositis.
• To evaluate the strength of the association and explore potential biases.
• To identify specific cancer risks associated with different myositis subtypes.

Main Methods:

• Review of recent population-based cohort studies.
• Analysis of studies utilizing pathologic criteria to distinguish myositis subtypes.
• Examination of data to rule out diagnostic suspicion or surveillance bias.

Main Results:

• Recent evidence confirms a robust association between malignancy and dermatomyositis and polymyositis.
• The association between polymyositis and malignancy appears stronger than previously reported, with less evidence of misclassification.
• Ovarian and lung cancers are linked to dermatomyositis; lung cancer and non-Hodgkin's lymphoma are linked to polymyositis.
• Inclusion body myositis is also associated with malignancy.
• Clinical courses of myositis and cancer sometimes mirror each other, suggesting a paraneoplastic relationship.

Conclusions:

• The association between inflammatory myopathies and malignancy is well-established and strengthened by recent data.
• The findings support the concept of myositis as a potential paraneoplastic disorder in some cases.
• Further research is needed to precisely define individual cancer risks for each myositis subtype.